Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis.

Détails

ID Serval
serval:BIB_6D5143ADBBE0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis.
Périodique
Clinical Nephrology
Auteur(s)
Trachsler J., Glück Z., Dickenmann M., Gauthier T., Brünisholz M., Martin P.Y., Burnier M., Wahl C., Wüthrich R.P.
ISSN
0301-0430 (Print)
ISSN-L
0301-0430
Statut éditorial
Publié
Date de publication
2009
Volume
71
Numéro
6
Pages
697-702
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
AIM: To document the feasibility and report the results of dosing darbepoetin-alpha at extended intervals up to once monthly (QM) in a large dialysis patient population.
MATERIAL: 175 adult patients treated, at 23 Swiss hemodialysis centres, with stable doses of any erythropoiesis-stimulating agent who were switched by their physicians to darbepoetin-alpha treatment at prolonged dosing intervals (every 2 weeks [Q2W] or QM).
METHOD: Multicentre, prospective, observational study. Patients' hemoglobin (Hb) levels and other data were recorded 1 month before conversion (baseline) to an extended darbepoetin-alpha dosing interval, at the time of conversion, and once monthly thereafter up to the evaluation point (maximum of 12 months or until loss to follow-up).
RESULTS: Data for 161 evaluable patients from 23 sites were included in the final analysis. At 1 month prior to conversion, 73% of these patients were receiving darbepoetin-alpha weekly (QW) and 27% of the patients biweekly (Q2W). After a mean follow-up of 9.5 months, 34% received a monthly (QM) dosing regimen, 52% of the patients were receiving darbepoetin-alpha Q2W, and 14% QW. The mean (SD) Hb concentration at baseline was 12.3 +/- 1.2 g/dl, compared to 11.9 +/- 1.2 g/dl at the evaluation point. The corresponding mean weekly darbepoetin-alpha dose was 44.3 +/- 33.4 microg at baseline and 37.7 +/- 30.8 microg at the evaluation point.
CONCLUSIONS: Conversion to extended darbepoetin-alpha dosing intervals of up to QM, with maintenance of initial Hb concentrations, was successful for the majority of stable dialysis patients.
Mots-clé
Aged, Algorithms, Anemia/blood, Anemia/etiology, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Monitoring/methods, Erythropoietin/administration & dosage, Erythropoietin/analogs & derivatives, Feasibility Studies, Female, Hematinics/administration & dosage, Hemoglobins/analysis, Humans, Kidney Failure, Chronic/blood, Kidney Failure, Chronic/complications, Male, Middle Aged, Prospective Studies, Renal Dialysis/statistics & numerical data, Treatment Outcome
Pubmed
Web of science
Création de la notice
09/02/2010 16:57
Dernière modification de la notice
03/03/2018 18:07
Données d'usage